# Core D: Biomarkers and Bioinformatics

> **NIH NIH P01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $541,086

## Abstract

Abstract 
The overall aim of Core D is to provide correlative biomarker analyses of primary specimens in the MPN-RC 
tissue bank as well as from samples arising from all MPN-RC clinical trials and prospective tissue banking 
efforts. Core D will carry out assessment of somatic genomic alterations on all MPN-RC samples derived from 
tissue banking efforts, and from therapeutic trials at baseline and the time of response assessment. The core 
will also carry out dynamic analyses of other mechanism-based biomarkers (such as serum cytokines, gene 
expression profiling, cytogenetics, and histopathology) which pertain to each of the biologic and clinical studies 
in Projects 1-4. The use of genomic profiling will provide Projects 1-3 with the ability to select genetically 
annotated samples for biologic studies aimed at investigating the relationship between somatic mutations, 
biological features of disease pathogenesis, and therapeutic dependencies. The goal of these assays is to 
provide comprehensive genetic and biologic correlative studies as well as to help determine the mechanistic 
impact of the hypothesis-driven therapeutic interventions of clinical trials in Project 4. The core will also perform 
and analyze assays for Project 1-3, which are common to these projects. The proposed analyses will result in 
integrated genomic, gene expression, and cytokine data of a large number of clinically annotated and 
homogenously treated patients. As well, the clinical trials proposed in Project 4 are mechanistically based, and 
stem from work in Projects 1-3. The correlative biomarker assays are directly related to the proposed 
mechanisms of action of the therapeutic agents delineated and which will be investigated in Project 4. These 
studies will allow for an assessment of the mechanistic impact of specific therapeutic interventions and allow 
us to credential novel therapeutic targets and pathways. As well, these studies will allow biological assessment 
of treatment responders and non-responders, thus giving insight into mechanisms of resistance. Importantly, 
we have developed rigorous organizational tools in order to maintain data integrity, traceability and 
reproducibility standards when dealing with the amount and the variety of data involved in the large-scale 
biomarker analyses for this core. The integration of state-of-the-art and novel biomarker assays offered by 
Core D, with robust preclinical and clinical studies will afford a unique opportunity to gain new genomic, 
epigenomic and biologic insights into MPN pathogenesis.

## Key facts

- **NIH application ID:** 10360656
- **Project number:** 5P01CA108671-14
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Raajit Rampal
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $541,086
- **Award type:** 5
- **Project period:** 2006-07-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10360656

## Citation

> US National Institutes of Health, RePORTER application 10360656, Core D: Biomarkers and Bioinformatics (5P01CA108671-14). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10360656. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*